Bladder Cancer: Chemoprevention, complementary approaches and budgetary considerations

References

• Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315–30
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• Marcus PM, Hayes RB, Vineis P, GarciaClosas M, Caporaso NE, Autrup H, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene–environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9: 461–7
   PubMed Web of Science ®Google Scholar
• Tripathi A, Folsom AR, Anderson KE. Risk factors for urinary bladder carcinoma in postmenopausal women – the Iowa women's health study. Cancer 2002; 95: 2316–23
   PubMed Web of Science ®Google Scholar
• Miyakawa M, Tachibana M, Miyakawa A, Yoshida K, Shimada N, Murai M, et al. Re-evaluation of the latent period of bladder cancer in dyestuff-plant workers in Japan. Int J Urol 2001; 8: 423–30
   PubMed Web of Science ®Google Scholar
• Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178: 62–7
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2004; 13: 920–7
   PubMed Web of Science ®Google Scholar
• Alberg AJ, Kouzis A, Genkinger JM, Gallicchio L, Burke AE, Hoffman SC, et al. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am J Epidemiol 2007; 165: 660–6
   PubMed Web of Science ®Google Scholar
• Baena AV, Allam MF, Diaz-Molina C, Del Castillo AS, Abdel-Rahman AG, Navajas RF. Urinary bladder cancer and the petroleum industry: a quantitative review. Eur J Cancer Prev 2006; 15: 493–7
   PubMed Web of Science ®Google Scholar
• Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J 2006; 99: 1256–63
   PubMed Web of Science ®Google Scholar
• Youakim S. Risk of cancer among firefighters: a quantitative review of selected malignancies. Arch Environ Occup Health 2006; 61: 223–31
   PubMed Web of Science ®Google Scholar
• Vineis P, Simonato L. Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. Arch Environ Health 1991; 46: 6–15
   PubMed Web of Science ®Google Scholar
• Ayotte JD, Baris D, Cantor KP, Colt J, Robinson GR, Lubin JH, et al. Bladder cancer mortality and private well use in New England: an ecological study. J Epidemiol Community Health 2006; 60: 168–72
   PubMed Web of Science ®Google Scholar
• Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S, et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 2007; 99: 920–8
   PubMed Web of Science ®Google Scholar
• Villanueva CM, Fernandez F, Malats N, Grimalt JO, Kogevinas M. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health 2003; 57: 166–73
   PubMed Web of Science ®Google Scholar
• Serretta V, Morgia G, Altieri V, Pavone-Macaluso M, Scuto F, Allegro R, et al. Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from Gruppo Studi Tumori Urologici Foundation. Urol Int 2006; 77: 152–8
   PubMed Web of Science ®Google Scholar
• Sanderson S, Salanti G, Higgns J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol 2007; 166: 741–51
   PubMed Web of Science ®Google Scholar
• ProbstHensch NM, Bell DA, Watson MA, Skipper PL, Tannenbaum SR, Chan KK, et al. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl–hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 2000; 9: 619–23
   PubMed Web of Science ®Google Scholar
• Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 649–59
   PubMed Web of Science ®Google Scholar
• Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, Chanock S, et al. Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet 2007; 121: 233–42
   PubMed Web of Science ®Google Scholar
• Figueroa JD, Malats N, Rothman N, Real FX, Silverman D, Kogevinas M, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis 2007; 28: 1788–93
   PubMed Web of Science ®Google Scholar
• Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, et al. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 2007; 28: 2160–5
   PubMed Web of Science ®Google Scholar
• Wu X, Lin J, Grossman HB, Huang M, Gu J, Etzel CJ, et al. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol 2007; 25: 4974–81
   PubMed Web of Science ®Google Scholar
• Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994; 151: 21–6
   PubMed Web of Science ®Google Scholar
• Prout GRJr, Barton BA. 13-cis-Retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J Cell Biochem Suppl 1992; 16I: 148–52
   PubMedGoogle Scholar
• Zou CP, Zhou JW, Qian LX, Feugang JM, Liu J, Wang XR, et al. Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells. Front Biosci 2006; 11: 2007–16
   PubMed Web of Science ®Google Scholar
• Decensi A, Bruno S, Costantini M, Torrisi R, Curotto A, Gatteschi B, et al. Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst 1994; 86: 138–40
   PubMedGoogle Scholar
• Bruno S, Torrisi R, Costantini M, Baglietto L, Fontana V, Gatteschi B, et al. Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. J Cell Biochem 1999; 76: 311–21
   PubMed Web of Science ®Google Scholar
• Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, et al. Phase III prevention trial of fenretinide in patients with resected non muscle-invasive bladder cancer. Clin Cancer Res 2008; 14: 224–9
   PubMed Web of Science ®Google Scholar
• Studer UE, Jenzer S, Biedermann C, Chollet D, Kraft R, von Toggenburg H, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995; 28: 284–90
   PubMed Web of Science ®Google Scholar
• Uchida K, Seidenfeld J, Rademaker A, Oyasu R. Inhibitory action of alpha-difluoromethylornithine on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis. Cancer Res 1989; 49: 5249–53
   PubMed Web of Science ®Google Scholar
• Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, et al. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst 1993; 85: 732–7
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Messing EM, O'Fallon JR, Poon MA, Love RR, Quella SK, et al. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol Biomarkers Prev 1996; 5: 371–4
   PubMed Web of Science ®Google Scholar
• Messing E, Kim K, Sharkey F, Schultz M, Parnes H, Kim D, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006; 176: 500–4
   PubMed Web of Science ®Google Scholar
• Grossman HB. Selective COX-2 inhibitors as chemopreventive and therapeutic agents. Drugs Today (Barc) 2003; 39: 203–12
   PubMed Web of Science ®Google Scholar
• Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857–60
   PubMed Web of Science ®Google Scholar
• Kuska B. Calories and cancer: can we starve our way to health?. J Natl Cancer Inst 2000; 92: 1466–9
   PubMedGoogle Scholar
• Cohen LA, Choi KW, Wang CX. Influence of dietary fat, caloric restriction, and voluntary exercise on N-nitrosomethylurea-induced mammary tumorigenesis in rats. Cancer Res 1988; 48: 4276–83
   PubMed Web of Science ®Google Scholar
• Weindruch R. Effect of caloric restriction on age-associated cancers. Exp Gerontol 1992; 27: 575–81
   PubMed Web of Science ®Google Scholar
• Kritchevsky D. Caloric restriction and experimental carcinogenesis. Adv Exp Med Biol 1992; 322: 131–41
   PubMedGoogle Scholar
• Hursting SD, Perkins SN, Phang JM. Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci U S A 1994; 91: 7036–40
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999; 91: 512–23
   PubMedGoogle Scholar
• Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57: 4667–72
   PubMed Web of Science ®Google Scholar
• Willett WC. Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarkers Prev 2001; 10: 3–8
   PubMed Web of Science ®Google Scholar
• Vena JE, Graham S, Freudenheim J, Marshall J, Zielezny M, Swanson M, et al. Diet in the epidemiology of bladder cancer in western New York. Nutr Cancer 1992; 18: 255–64
   PubMed Web of Science ®Google Scholar
• Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 2006; 295: 1539–48
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006; 98: 1767–76
   PubMed Web of Science ®Google Scholar
• Kromhout D, Bloemberg B, Feskens E, Menotti A, Nissinen A. Saturated fat, vitamin C and smoking predict long-term population all-cause mortality rates in the Seven Countries Study. Int J Epidemiol 2000; 29: 260–5
   PubMed Web of Science ®Google Scholar
• Riboli E, Gonzalez CA, Lopez-Abente G, Errezola M, Izarzugaza I, Escolar A, et al. Diet and bladder cancer in Spain: a multi-centre case–control study. Int J Cancer 1991; 49: 214–9
   PubMed Web of Science ®Google Scholar
• Mills PK, Beeson WL, Phillips RL, Fraser GE. Bladder cancer in a low risk population: results from the Adventist Health Study. Am J Epidemiol 1991; 133: 230–9
   PubMed Web of Science ®Google Scholar
• Fraser GE. Associations between diet and cancer, ischemic heart disease, and all-cause mortality in non-Hispanic white California Seventh-day Adventists. Am J Clin Nutr 1999;70(3 Suppl):532–8S.
   PubMed Web of Science ®Google Scholar
• Bruemmer B, White E, Vaughan TL, Cheney CL. Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 1996; 144: 485–95
   PubMed Web of Science ®Google Scholar
• Steineck G, Hagman U, Gerhardsson M, Norell SE. Vitamin A supplements, fried foods, fat and urothelial cancer. A case–referent study in Stockholm in 1985–87. Int J Cancer 1990; 45: 1006–11
   PubMed Web of Science ®Google Scholar
• Augustsson K, Skog K, Jagerstad M, Dickman PW, Steineck G. Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. Lancet 1999; 353: 703–7
   PubMed Web of Science ®Google Scholar
• Nagano J, Kono S, Preston DL, Moriwaki H, Sharp GB, Koyama K, et al. Bladder-cancer incidence in relation to vegetable and fruit consumption: a prospective study of atomic-bomb survivors. Int J Cancer 2000; 86: 132–8
   PubMed Web of Science ®Google Scholar
• Claude J, Kunze E, Frentzel-Beyme R, Paczkowski K, Schneider J, Schubert H. Life-style and occupational risk factors in cancer of the lower urinary tract. Am J Epidemiol 1986; 124: 578–89
   PubMed Web of Science ®Google Scholar
• Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer 1992; 66: 673–9
   PubMed Web of Science ®Google Scholar
• Chyou PH, Nomura AM, Stemmermann GN. A prospective study of diet, smoking, and lower urinary tract cancer. Ann Epidemiol 1993; 3: 211–6
   PubMedGoogle Scholar
• Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci EL. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst 1999; 91: 605–13
   PubMed Web of Science ®Google Scholar
• Pantuck EJ, Hsiao KC, Loub WD, Wattenberg LW, Kuntzman R, Conney AH. Stimulatory effect of vegetables on intestinal drug metabolism in the rat. J Pharmacol Exp Ther 1976; 198: 278–83
   PubMed Web of Science ®Google Scholar
• Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, Anderson KE, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25: 88–95
   PubMed Web of Science ®Google Scholar
• Sparnins VL, Venegas PL, Wattenberg LW. Glutathione S-transferase activity: enhancement by compounds inhibiting chemical carcinogenesis and by dietary constituents. J Natl Cancer Inst 1982; 68: 493–6
   PubMed Web of Science ®Google Scholar
• Aspry KE, Bjeldanes LF. Effects of dietary broccoli and butylated hydroxyanisole on liver-mediated metabolism of benzo[a]pyrene. Food Chem Toxicol 1983; 21: 133–42
   PubMed Web of Science ®Google Scholar
• Bradfield CA, Chang Y, Bjeldanes LF. Effects of commonly consumed vegetables on hepatic xenobiotic-metabolizing enzymes in the mouse. Food Chem Toxicol 1985; 23: 899–904
   PubMed Web of Science ®Google Scholar
• Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A 1992; 89: 2399–403
   PubMed Web of Science ®Google Scholar
• Schabath MB, Spitz MR, Lerner SP, Pillow PC, Hernandez LM, Delclos GL, et al. Case–control analysis of dietary folate and risk of bladder cancer. Nutr Cancer 2005; 53: 144–51
   PubMed Web of Science ®Google Scholar
• Radosavljevic V, Jankovic S, Marinkovic J, Dokic M. Diet and bladder cancer: a case–control study. Int Urol Nephrol 2005; 37: 283–9
   PubMedGoogle Scholar
• Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 2007; 55: 224–36
   PubMed Web of Science ®Google Scholar
• Garcia R, Gonzalez CA, Agudo A, Riboli E. High intake of specific carotenoids and flavonoids does not reduce the risk of bladder cancer. Nutr Cancer 1999; 35: 212–4
   PubMed Web of Science ®Google Scholar
• Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999; 91: 317–31
   PubMed Web of Science ®Google Scholar
• Okajima E, Ozono S, Endo T, Majima T, Tsutsumi M, Fukuda T, et al. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Jpn J Cancer Res 1997; 88: 543–52
   PubMedGoogle Scholar
• Nomura AM, Kolonel LN, Hankin JH, Yoshizawa CN. Dietary factors in cancer of the lower urinary tract. Int J Cancer 1991; 48: 199–205
   PubMed Web of Science ®Google Scholar
• Comstock GW, Helzlsouer KJ, Bush TL. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. Am J Clin Nutr 1991;53(1 Suppl):260–4S.
   Web of Science ®Google Scholar
• Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res 1989; 49: 6144–8
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 1767–76
   PubMed Web of Science ®Google Scholar
• Hung RJ, Zhang ZF, Rao JY, Pantuck A, Reuter VE, Heber D, et al. Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol 2006; 176: 1192–7
   PubMed Web of Science ®Google Scholar
• Steinmaus CM, Nunez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000; 151: 693–702
   PubMed Web of Science ®Google Scholar
• Ernst E. Cardiovascular effects of garlic (Allium sativum): a review. Pharmatherapeutica 1987; 5: 83–9
   PubMedGoogle Scholar
• Wargovich MJ, Uda N, Woods C, Velasco M, McKee K. Allium vegetables: their role in the prevention of cancer. Biochem Soc Trans 1996; 24: 811–4
   PubMed Web of Science ®Google Scholar
• Challier B, Perarnau JM, Viel JF. Garlic, onion and cereal fibre as protective factors for breast cancer: a French case–control study. Eur J Epidemiol 1998; 14: 737–47
   PubMed Web of Science ®Google Scholar
• Levi F, Pasche C, La Vecchia C, Lucchini F, Franceschi S. Food groups and colorectal cancer risk. Br J Cancer 1999; 79: 1283–7
   PubMed Web of Science ®Google Scholar
• Gao CM, Takezaki T, Ding JH, Li MS, Tajima K. Protective effect of allium vegetables against both esophageal and stomach cancer: a simultaneous case–referent study of a high-epidemic area in Jiangsu Province, China. Jpn J Cancer Res 1999; 90: 614–21
   PubMedGoogle Scholar
• Fleischauer AT, Poole C, Arab L. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am J Clin Nutr 2000; 72: 1047–52
   PubMed Web of Science ®Google Scholar
• Fleischauer AT, Arab L. Garlic and cancer: a critical review of the epidemiologic literature. J Nutr 2001; 131(3s)1032–40
   PubMed Web of Science ®Google Scholar
• Lau BH, Woolley JL, Marsh CL, Barker GR, Koobs DH, Torrey RR. Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma. J Urol 1986; 136: 701–5
   PubMed Web of Science ®Google Scholar
• Marsh CL, Torrey RR, Woolley JL, Barker GR, Lau BH. Superiority of intravesical immunotherapy with Corynebacterium parvum and Allium sativum in control of murine bladder cancer. J Urol 1987; 137: 359–62
   PubMed Web of Science ®Google Scholar
• Lamm DL, Riggs DR. Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. J Nutr 2001; 131: 1067–70S
   PubMed Web of Science ®Google Scholar
• Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993; 119: 599–605
   PubMed Web of Science ®Google Scholar
• Koscielny J, Klussendorf D, Latza R, Schmitt R, Radtke H, Siegel G, et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis 1999; 144: 237–49
   PubMed Web of Science ®Google Scholar
• Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med 2000; 133: 420–9
   PubMed Web of Science ®Google Scholar
• Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998; 316: 1213–20
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999; 159: 1793–802
   PubMed Web of Science ®Google Scholar
• Sigounas G, Anagnostou A, Steiner M. dl-Alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer 1997; 28: 30–5
   PubMed Web of Science ®Google Scholar
• Pinto JT, Qiao CH, Xing J, Suffoletto BP, Schubert KB, Rivlin RS, et al. Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine. Prostate 2000; 45: 304–14
   PubMed Web of Science ®Google Scholar
• Key TJA, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case–control study of diet and prostate cancer. Br J Cancer 1997; 76: 678–87
   PubMed Web of Science ®Google Scholar
• Dorant E, van den Brandt PA, Goldbohm RA. Allium vegetable consumption, garlic supplement intake, and female breast carcinoma incidence. Breast Cancer Res Treat 1995; 33: 163–70
   PubMed Web of Science ®Google Scholar
• Dorant E, van den Brandt PA, Goldbohm RA. A prospective cohort study on the relationship between onion and leek consumption, garlic supplement use and the risk of colorectal carcinoma in The Netherlands. Carcinogenesis 1996; 17: 477–84
   PubMed Web of Science ®Google Scholar
• Dorant E, van den Brandt PA, Goldbohm RA. A prospective cohort study on Allium vegetable consumption, garlic supplement use, and the risk of lung carcinoma in The Netherlands. Cancer Res 1994; 54: 6148–53
   PubMed Web of Science ®Google Scholar
• Dorant E, van den Brandt PA, Goldbohm RA, Sturmans F. Consumption of onions and a reduced risk of stomach carcinoma. Gastroenterology 1996; 110: 12–20
   PubMed Web of Science ®Google Scholar
• Ashughyan VR, Marihart S, Djavan B. Chemopreventive trials in urologic cancer. Rev Urol 2006; 8: 8–13
   PubMedGoogle Scholar
• Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000; 57: 1221–7
   PubMed Web of Science ®Google Scholar
• Moyad MA. Soy, disease prevention, and prostate cancer. Semin Urol Oncol 1999; 17: 97–102
   PubMedGoogle Scholar
• Moyad MA, Sakr WA, Hirano D, Miller GJ. Complementary medicine for prostate cancer: effects of soy and fat consumption. Rev Urol 2001; 3(Suppl 2)S20–30
   PubMedGoogle Scholar
• Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991; 83: 541–6
   PubMed Web of Science ®Google Scholar
• Mokhtar NM, el-Aaser AA, el-Bolkainy MN, Ibrahim HA, el-Din NB, Moharram NZ. Effect of soybean feeding on experimental carcinogenesis – III. Carcinogenecity of nitrite and dibutylamine in mice: a histopathological study. Eur J Cancer Clin Oncol 1988; 24: 403–11
   PubMedGoogle Scholar
• Zhou JR, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 1998; 58: 5231–8
   PubMed Web of Science ®Google Scholar
• Su SJ, Yeh TM, Lei HY, Chow NH. The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 2000; 6: 230–6
   PubMed Web of Science ®Google Scholar
• Su SJ, Lai MD, Yeh TM, Chow NH. Overexpression of HER-2/neu enhances the sensitivity of human bladder cancer cells to urinary isoflavones. Eur J Cancer 2001; 37: 1413–8
   PubMed Web of Science ®Google Scholar
• Lu CM, Lan SJ, Lee YH, Huang JK, Huang CH, Hsieh CC. Tea consumption: fluid intake and bladder cancer risk in southern Taiwan. Urology 1999; 54: 823–8
   PubMed Web of Science ®Google Scholar
• Seow A, Shi CY, Franke AA, Hankin JH, Lee HP, Yu MC. Isoflavonoid levels in spot urine are associated with frequency of dietary soy intake in a population-based sample of middle-aged and older Chinese in Singapore. Cancer Epidemiol Biomarkers Prev 1998; 7: 135–40
   PubMed Web of Science ®Google Scholar
• Sun CL, Yuan JM, Arakawa K, Low SH, Lee HP, Yu MC. Dietary soy and increased risk of bladder cancer: the Singapore Chinese health study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1674–7
   PubMed Web of Science ®Google Scholar
• Sun CL, Yuan JM, Wang XL, Gao YT, Ross RK, Yu MC. Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China. Int J Cancer 2004; 112: 319–23
   PubMed Web of Science ®Google Scholar
• Ip C. The chemopreventive role of selenium in carcinogenesis. Adv Exp Med Biol 1986; 206: 431–47
   PubMedGoogle Scholar
• Shamberger RJ, Tytko SA, Willis CE. Antioxidants and cancer. Part VI. Selenium and age-adjusted human cancer mortality. Arch Environ Health 1976; 31: 231–5
   PubMedGoogle Scholar
• Schrauzer GN, White DA, Schneider CJ. Cancer mortality correlation studies – III: statistical associations with dietary selenium intakes. Bioinorg Chem 1977; 7: 23–31
   PubMedGoogle Scholar
• Mohandas J, Marshall JJ, Duggin GG, Horvath JS, Tiller DJ. Low activities of glutathione-related enzymes as factors in the genesis of urinary bladder cancer. Cancer Res 1984; 44: 5086–91
   PubMed Web of Science ®Google Scholar
• Chow CK. Nutritional influence on cellular antioxidant defense systems. Am J Clin Nutr 1979; 32: 1066–81
   PubMed Web of Science ®Google Scholar
• Salonen JT, Alfthan G, Huttunen JK, Puska P. Association between serum selenium and the risk of cancer. Am J Epidemiol 1984; 120: 342–9
   PubMed Web of Science ®Google Scholar
• Nomura A, Heilbrun LK, Morris JS, Stemmermann GN. Serum selenium and the risk of cancer, by specific sites: case–control analysis of prospective data. J Natl Cancer Inst 1987; 79: 103–8
   PubMed Web of Science ®Google Scholar
• Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case–control study on bladder cancer. Int J Urol 2006; 13: 1180–4
   PubMed Web of Science ®Google Scholar
• Robinson MF, Godfrey PJ, Thomson CD, Rea HM, van Rij AM. Blood selenium and glutathione peroxidase activity in normal subjects and in surgical patients with and without cancer in New Zealand. Am J Clin Nutr 1979; 32: 1477–85
   PubMed Web of Science ®Google Scholar
• Sundstrom H, Yrjanheikki E, Kauppila A. Serum selenium in patients with ovarian cancer during and after therapy. Carcinogenesis 1984; 5: 731–4
   PubMed Web of Science ®Google Scholar
• Dworkin BM, Rosenthal WS, Mittelman A, Weiss L, Applebee-Brady L, Arlin Z. Selenium status and the polyp–cancer sequence: a colonoscopically controlled study. Am J Gastroenterol 1988; 83: 748–51
   PubMed Web of Science ®Google Scholar
• Reinhold U, Biltz H, Bayer W, Schmidt KH. Serum selenium levels in patients with malignant melanoma. Acta Derm Venereol (Stockh) 1989; 69: 132–6
   PubMed Web of Science ®Google Scholar
• Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, et al. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 1995; 87: 497–505
   PubMed Web of Science ®Google Scholar
• Michaud DS, DeVivo I, Morris JS, Giovannucci E. Toenail selenium concentrations and bladder cancer risk in women and men. Br J Cancer 2005; 93: 804–6
   PubMed Web of Science ®Google Scholar
• Colditz GA. Selenium and cancer prevention. Promising results indicate further trials required. JAMA 1996; 276: 1984–5
   PubMed Web of Science ®Google Scholar
• Clark LC, Combs GFJr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group [published erratum appears in JAMA 1997;277:1520]. JAMA 1996; 276: 1957–63
   PubMed Web of Science ®Google Scholar
• Menkes MS, Comstock GW, Vuilleumier JP, Helsing KJ, Rider AA, Brookmeyer R. Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. N Engl J Med 1986; 315: 1250–4
   PubMed Web of Science ®Google Scholar
• Lijinsky W, Milner JA, Kovatch RM, Thomas BJ. Lack of effect of selenium on induction of tumors of esophagus and bladder in rats by two nitrosamines. Toxicol Ind Health 1989; 5: 63–72
   PubMed Web of Science ®Google Scholar
• Burk RF, Hill KE. Regulation of selenoproteins. Annu Rev Nutr 1993; 13: 65–81
   PubMed Web of Science ®Google Scholar
• Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992; 18: 1–29
   PubMed Web of Science ®Google Scholar
• Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996; 96: 1027–39
   PubMed Web of Science ®Google Scholar
• Patterson RE, White E, Kristal AR, Neuhouser ML, Potter JD. Vitamin supplements and cancer risk: the epidemiologic evidence. Cancer Causes Control 1997; 8: 786–802
   PubMed Web of Science ®Google Scholar
• Pipkin GE, Schlegel JU, Nishimura R, Shultz GN. Inhibitory effect of l-ascorbate on tumor formation in urinary bladders implanted with 3-hydroxyanthranilic acid. Proc Soc Exp Biol Med 1969; 131: 522–4
   PubMedGoogle Scholar
• Fukushima S, Kurata Y, Shibata M, Ikawa E, Ito N. Promotion by ascorbic acid, sodium erythorbate and ethoxyquin of neoplastic lesions in rats initiated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Lett 1984; 23: 29–37
   PubMed Web of Science ®Google Scholar
• Fukushima S, Imaida K, Sakata T, Okamura T, Shibata M, Ito N. Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res 1983; 43: 4454–7
   PubMed Web of Science ®Google Scholar
• Risch HA, Burch JD, Miller AB, Hill GB, Steele R, Howe GR. Dietary factors and the incidence of cancer of the urinary bladder. Am J Epidemiol 1988; 127: 1179–91
   PubMed Web of Science ®Google Scholar
• Kolonel LN, Hinds MW, Nomura AM, Hankin JH, Lee J. Relationship of dietary vitamin A and ascorbic acid intake to the risk for cancers of the lung, bladder, and prostate in Hawaii. Natl Cancer Inst Monogr 1985; 69: 137–42
   PubMedGoogle Scholar
• Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci E. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 2000; 152: 1145–53
   PubMed Web of Science ®Google Scholar
• Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174: 937–42
   PubMed Web of Science ®Google Scholar
• Stephenson CM, Levin RD, Lis CG. Phase 1 trial of high-dose intravenous vitamin C treatment for patients with cancer. J Am Osteopath Assoc 2007; 107: 212–3
   PubMedGoogle Scholar
• Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci 2007; 22: 7–11
   PubMed Web of Science ®Google Scholar
• Riordan HD, Casciari JJ, Gonzalez MJ, Riordan NH, Miranda-Massari JR, Taylor P, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005; 24: 269–76
   PubMedGoogle Scholar
• Steinmetz KA, Potter JD. Vegetables, fruit, and cancer. II. Mechanisms. Cancer Causes Control 1991; 2: 427–42
   PubMed Web of Science ®Google Scholar
• Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–35.
   PubMed Web of Science ®Google Scholar
• Virtamo J, Edwards BK, Virtanen M, Taylor PR, Malila N, Albanes D, et al. Effects of supplemental alpha-tocopherol and beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland). Cancer Causes Control 2000; 11: 933–9
   PubMed Web of Science ®Google Scholar
• Coulter ID, Hardy ML, Morton SC, Hilton LG, Tu W, Valentine D, et al. Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer. J Gen Intern Med 2006; 21: 735–44
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842–57
   PubMed Web of Science ®Google Scholar
• Miller ER, III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37–46
   PubMed Web of Science ®Google Scholar
• Konety BR, Lavelle JP, Pirtskalaishvili G, Dhir R, Meyers SA, Nguyen TST, et al. Effects of vitamin D (Calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001; 165: 253–8
   PubMed Web of Science ®Google Scholar
• Ali MM, Vaidya V. Vitamin D and cancer. J Cancer Res Ther 2007; 3: 225–30
   PubMedGoogle Scholar
• Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer 2007; 120: 140–6
   PubMed Web of Science ®Google Scholar
• Friedenreich CM. Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev 2001; 10: 287–301
   PubMed Web of Science ®Google Scholar
• McCann J. Obesity, cancer links prompt new recommendations. J Natl Cancer Inst 2001; 93: 901–2
   PubMedGoogle Scholar
• Knekt P, Heliovaara M, Rissanen A, Aromaa A, Seppanen R, Teppo L, et al. Leanness and lung-cancer risk. Int J Cancer 1991; 49: 208–13
   PubMed Web of Science ®Google Scholar
• Goodman MT, Wilkens LR. Relation of body size and the risk of lung cancer. Nutr Cancer 1993; 20: 179–86
   PubMed Web of Science ®Google Scholar
• Kubik A, Zatloukal P, Boyle P, Robertson C, Gandini S, Tomasek L, et al. A case–control study of lung cancer among Czech women. Lung Cancer 2001; 31: 111–22
   PubMed Web of Science ®Google Scholar
• Drinkard CR, Sellers TA, Potter JD, Zheng W, Bostick RM, Nelson CL, et al. Association of body mass index and body fat distribution with risk of lung cancer in older women. Am J Epidemiol 1995; 142: 600–7
   PubMed Web of Science ®Google Scholar
• Rauscher GH, Mayne ST, Janerich DT. Relation between body mass index and lung cancer risk in men and women never and former smokers. Am J Epidemiol 2000; 152: 506–13
   PubMed Web of Science ®Google Scholar
• Kabat GC. Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States. Lung Cancer 1996; 15: 1–20
   PubMed Web of Science ®Google Scholar
• Wolf A, Grossman B, Lerner S, Chang S, Spitz MR, Wu X. Body mass index and bladder cancer risk: a preliminary report. Proc AACR 2001; 42: 762–3
   Google Scholar
• Weinsier RL. Genes and obesity: is there reason to change our behaviors?. Ann Intern Med 1999; 130: 938–9
   PubMed Web of Science ®Google Scholar
• Hediger ML, Overpeck MD, Kuczmarski RJ, Ruan WJ. Association between infant breastfeeding and overweight in young children. JAMA 2001; 285: 2453–60
   PubMed Web of Science ®Google Scholar
• Gillman MW, Rifas-Shiman SL, Camargo CA, Jr, Berkey CS, Frazier AL, Rockett HR, et al. Risk of overweight among adolescents who were breastfed as infants. JAMA 2001; 285: 2461–7
   PubMed Web of Science ®Google Scholar
• Mydlo JH, Kanter JL, Kral JG, MacChia RJ. The role of obesity and diet in urological carcinogenesis. BJU Int 1999; 84: 225–34
   PubMed Web of Science ®Google Scholar
• Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001; 286: 921–9
   PubMed Web of Science ®Google Scholar
• Oyasu R, Hopp ML. The etiology of cancer of the bladder. Surg Gynecol Obstet 1974; 138: 97–108
   PubMedGoogle Scholar
• Melicow MM. Tumors of the bladder: a multifaceted problem. J Urol 1974; 112: 467–78
   PubMed Web of Science ®Google Scholar
• Jensen OM, Wahrendorf J, Knudsen JB, Sorensen BL. The Copenhagen case–control study of bladder cancer. II. Effect of coffee and other beverages. Int J Cancer 1986; 37: 651–7
   PubMed Web of Science ®Google Scholar
• Kunze E, Chang-Claude J, Frentzel-Beyme R. Life style and occupational risk factors for bladder cancer in Germany. A case–control study. Cancer 1992; 69: 1776–90
   PubMed Web of Science ®Google Scholar
• Cantor KP, Hoover R, Hartge P, Mason TJ, Silverman DT, Altman R, et al. Bladder cancer, drinking water source, and tap water consumption: a case–control study. J Natl Cancer Inst 1987; 79: 1269–79
   PubMed Web of Science ®Google Scholar
• Slattery ML, West DW, Robison LM. Fluid intake and bladder cancer in Utah. Int J Cancer 1988; 42: 17–22
   PubMed Web of Science ®Google Scholar
• Vena JE, Graham S, Freudenheim J, Marshall J, Zielezny M, Swanson M, et al. Drinking water, fluid intake, and bladder cancer in western New York. Arch Environ Health 1993; 48: 191–8
   PubMed Web of Science ®Google Scholar
• Howe GR, Burch JD, Miller AB, Cook GM, Esteve J, Morrison B, et al. Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst 1980; 64: 701–13
   PubMedGoogle Scholar
• Thomas DB, Uhl CN, Hartge P. Bladder cancer and alcoholic beverage consumption. Am J Epidemiol 1983; 118: 720–7
   PubMed Web of Science ®Google Scholar
• Brownson RC, Chang JC, Davis JR. Occupation, smoking, and alcohol in the epidemiology of bladder cancer. Am J Public Health 1987; 77: 1298–300
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Negri E, Decarli A, D'Avanzo B, Liberati C, Franceschi S. Dietary factors in the risk of bladder cancer. Nutr Cancer 1989; 12: 93–101
   PubMed Web of Science ®Google Scholar
• Viscoli CM, Lachs MS, Horwitz RI. Bladder cancer and coffee drinking: a summary of case–control research. Lancet 1993; 341: 1432–7
   PubMed Web of Science ®Google Scholar
• Stensvold I, Jacobsen BK. Coffee and cancer: a prospective study of 43, 000 Norwegian men and women. Cancer Causes Control 1994; 5: 401–8
   PubMed Web of Science ®Google Scholar
• Dunham LJ, Rabson AS, Stewart HL, Frank AS, Young JL. Rates, interview, and pathology study of cancer of the urinary bladder in New Orleans, Louisiana. J Natl Cancer Inst 1968; 41: 683–709
   PubMed Web of Science ®Google Scholar
• Wynder EL, Onderdonk J, Mantel N. An epidemiological investigation of cancer of the bladder. Cancer 1963; 16: 1388–407
   PubMed Web of Science ®Google Scholar
• Wilkins JR, III, Comstock GW. Source of drinking water at home and site-specific cancer incidence in Washington County, Maryland. Am J Epidemiol 1981; 114: 178–90
   PubMed Web of Science ®Google Scholar
• Morrison AS, Buring JE, Verhoek WG, Aoki K, Leck I, Ohno Y, et al. Coffee drinking and cancer of the lower urinary tract. J Natl Cancer Inst 1982; 68: 91–4
   PubMedGoogle Scholar
• Bruemmer B, White E, Vaughan TL, Cheney CL. Fluid intake and the incidence of bladder cancer among middle-aged men and women in a three-county area of Western Washington. Nutr Cancer 1997; 29: 163–8
   PubMed Web of Science ®Google Scholar
• Zeegers MPA, Volovics A, Dorant E, Goldbohm RA, vandenBrandt PA. Alcohol consumption and bladder cancer risk: results from the Netherlands cohort study. Am J Epidemiol 2001; 153: 38–41
   PubMed Web of Science ®Google Scholar
• Bianchi GD, Cerhan JR, Parker AS, Putnam SD, See WA, Lynch CF, et al. Tea consumption and risk of bladder and kidney cancers in a population-based case–control study. Am J Epidemiol 2000; 151: 377–83
   PubMed Web of Science ®Google Scholar
• Zeegers MP, Dorant E, Goldbohm RA, van den Brandt PA. Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. Cancer Causes Control 2001; 12: 231–8
   PubMed Web of Science ®Google Scholar
• Sala M, Cordier S, Chang-Claude J, Donato F, Escolar-Pujolar A, Fernandez F, et al. Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case–control studies in European countries. Cancer Causes Control 2000; 11: 925–31
   PubMed Web of Science ®Google Scholar
• Michaud DS, Kogevinas M, Cantor KP, Villanueva CM, Garcia-Closas M, Rothman N, et al. Total fluid and water consumption and the joint effect of exposure to disinfection by-products on risk of bladder cancer. Environ Health Perspect 2007; 115: 1569–72
   PubMed Web of Science ®Google Scholar
• Villanueva CM, Cantor KP, King WD, Jaakkola JJK, Cordier S, Lynch CF, et al. Total and specific fluid consumption as determinants of bladder cancer risk. Int J Cancer 2006; 118: 2040–7
   PubMed Web of Science ®Google Scholar
• Jones PA, Ross RK. Prevention of bladder cancer. N Engl J Med 1999; 340: 1424–6
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Schulman CC. Biological response modifiers for the treatment of superficial bladder tumors. Eur Urol 2000; 37(Suppl 3)10–5
   PubMedGoogle Scholar
• Kim JC, Steinberg GD. The limits of bacillus Calmette–Guerin for carcinoma in situ of the bladder. J Urol 2001; 165: 745–56
   PubMed Web of Science ®Google Scholar
• Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU group. EORTC Genito-urinary Tract Cancer Cooperative Group. Eur Urol 1995; 27: 110–6
   PubMed Web of Science ®Google Scholar
• Byar D, Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977; 10: 556–61
   PubMedGoogle Scholar
• Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP study group. Eur Urol 1995; 27: 104–9
   PubMed Web of Science ®Google Scholar
• Saavedra JM. Clinical applications of probiotic agents. Am J Clin Nutr; :S 2001; 73: 1147–51
   PubMed Web of Science ®Google Scholar
• Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–9
   PubMed Web of Science ®Google Scholar
• Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, et al. Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer. J Urol 2008; 179: 485–90
   PubMed Web of Science ®Google Scholar
• Neymark N, Torfs K. Economics of urinary tract cancers: state of the art. Eur Urol 1997; 31(Suppl 1)72–81
   PubMedGoogle Scholar
• Hedelin H, Holmäng S, Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 2002; 36: 344–7
   PubMed Web of Science ®Google Scholar
• Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33: 828–41
   PubMed Web of Science ®Google Scholar
• Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int 2005; 95: 59–63
   PubMed Web of Science ®Google Scholar
• Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. J Urol 2007; 177: 1636–45
   PubMed Web of Science ®Google Scholar
• Ellwein LB, Farrow GM, Friedell GH, Greenfield RE. An assessment of the impact of urine cytology screening using a computer-based model of bladder cancer. Urol Clin North Am 1984; 11: 585–98
   PubMed Web of Science ®Google Scholar
• Messing EM, Young TB, Hunt VB, Newton MA, Bram LL, Vaillancourt A, et al. Hematuria home screening: repeat testing results. J Urol 1995; 154: 57–61
   PubMed Web of Science ®Google Scholar
• Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 2006; 24: 338–43
   PubMed Web of Science ®Google Scholar
• Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006; 107: 2173–9
   PubMed Web of Science ®Google Scholar
• Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 2006; 107: 982–90
   PubMed Web of Science ®Google Scholar
• Lotan Y, Svatek RS, Malats N. Screening for bladder cancer: a perspective. World J Urol 2008; 26: 13–8
   PubMed Web of Science ®Google Scholar
• Konety BR, Dhawan V, Allareddy V, ODonnell MA. Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper? J Urol 2004;172:1056–61.
   PubMed Web of Science ®Google Scholar
• Burger M, Zaak D, Stief CG, Filbeck T, Wieland WF, Roessler W, et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 2007; 52: 142–7
   PubMed Web of Science ®Google Scholar
• Racioppi M, Volpe A, Falabella R, Pinto F, Sacco E, Gulino G, et al. The cost of treatment and follow-up of bladder cancer in Italy. Arch Ital Urol Androl 2007; 79: 111–7
   PubMedGoogle Scholar
• Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, et al. Intravesical instillation of bacille Calmette–Guerin for superficial bladder cancer: cost-effectiveness analysis. Urology 2007; 69: 275–9
   PubMed Web of Science ®Google Scholar
• Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA Journal of the American Medical Association 2006; 295: 299–305
   PubMed Web of Science ®Google Scholar
• Dino G, Horn K, Abdulkadri A, Kalsekar I, Branstetter S. Cost-effectiveness analysis of the not on tobacco program for adolescent smoking cessation. Prev Sci 2008.
   PubMed Web of Science ®Google Scholar
• Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 2007; 370: 2044–53
   PubMed Web of Science ®Google Scholar
• Irigaray P, Newby JA, Clapp R, Hardell L, Howard V, Montagnier L, et al. Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed Pharmacother 2007; 61: 640–58
   PubMed Web of Science ®Google Scholar
• Kogevinas M, ‘t Mannetje A, Cordier S, Ranft U, Gonzalez CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 2003; 14: 907–14
   PubMed Web of Science ®Google Scholar
• Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 2005; 66: 1209–12
   PubMed Web of Science ®Google Scholar
• Qin J, Xie LP, Zheng XY, Wang YB, Bai Y, Shen HF, et al. A component of green tea, (–)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun 2007; 354: 852–7
   PubMed Web of Science ®Google Scholar